Introduction
Epidemiology
- Incidence: 0.10 cases per 100,000 person-years
- Peak incidence: 20-30 years
- Sex ratio: 1:1
<1 | 1-5 | 6+ | 16+ | 30+ | 40+ | 50+ | 60+ | 70+ | 80+ |
Clinical features
Seizures
Dyskinesias
Autonomic instability
Investigations
CSF may demonstrate pleiocytosis but can be normal initially.
Antibodies
- Anti-MuSK is an autoantibody specific to muscle kinase in myasthenia gravis with no evidence of a thymoma and without antibodies to acetylcholine receptors.
- Anti-GM1 is an autoantibody specific to acute inflammatory demyelinating polyneuropathy (AIDP) variant of Guillain-Barre syndrome.